The NGF System and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain

The General Assembly is the ultimate decision-making body of the Consortium.


Antonino Cattaneo, SNS Chair
Mara D’Onofrio, EBRI
Anders Nykjaer AU
Tibor Harkany, MUW
Simon Westbrook, LEVICEPT
Marzia Malcangio, KCL
Juan Carlos Arevalo, USAL
Anna Moles, GENOMNIA
Giovanni Marsicano INSERM


It assumes overall responsibility for liaison among the partner in relation to the project, for analysing and approving the results, for proper administration of the project and for implementation of the provisions contained in the Consortium Agreement

It decides on:

  1. Content, finances and intellectual property rights;
  2. Evolution of the Consortium.